William Blair research analyst Matt Phipps joined CNBC’s “Worldwide Exchange” to discuss the implications for pharmaceutical companies that have their drugs listed on Medicare’s price negotiation roster.
Equity Research
Matt Phipps Guests on CNBC
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
First Advantage Corporation: Initiation of Research Coverage
William Blair initiated research coverage of First Advantage Corporation (FA $15.32), a leading global provider of technology-enabled background screening products.
Read moreOn Holding AG: Initiation of Research Coverage
William Blair initiated research coverage of On Holding AG (ONON $32.87), a fast-growing performance and lifestyle brand based in Switzerland selling athletic footwear, primarily in running, but with a growing presence in newer categories and apparel.
Read moreCullinan Oncology, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Cullinan Oncology, Inc. (CGEM $17.37), a company focused on advancing modality-agnostic targeted therapies for cancer, with a broad pipeline encompassing small molecules and multifunctional therapies across a diverse range of oncologic targets.
Read more